Your browser doesn't support javascript.
loading
Dysregulation in mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells
Sofia Appelberg; Soham Gupta; Anoop T Ambikan; Flora Mikaeloff; Akos Vegvari; Sara Svensson Akusjarvi; Rui Benfeitas; Maike Sperk; Marie Stahlberg; Shuba Krishnan; Kamal Singh; Josef M Penninger; Ali Mirazimi; Ujjwal Neogi.
Afiliação
  • Sofia Appelberg; Public Health Agency of Sweden, Solna, Sweden
  • Soham Gupta; Karolinska Institutet
  • Anoop T Ambikan; Karolinska Institute
  • Flora Mikaeloff; Karolinska Institute
  • Akos Vegvari; Karolinska Institute
  • Sara Svensson Akusjarvi; Karolinska Institute
  • Rui Benfeitas; Stockholm University
  • Maike Sperk; Karolinska Institute
  • Marie Stahlberg; Karolinska Institute
  • Shuba Krishnan; Karolinska Institute
  • Kamal Singh; University of Missouri
  • Josef M Penninger; University of British Columbia
  • Ali Mirazimi; Public Health Agency of Sweden
  • Ujjwal Neogi; Karolinska Institutet
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-070383
ABSTRACT
How Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections engage cellular host pathways and innate immunity in infected cells remain largely elusive. We performed an integrative proteo-transcriptomics analysis in SARS-CoV-2 infected HuH7 cells to map the cellular response to the invading virus over time. We identified four pathways, ErbB, HIF-1, mTOR and TNF signaling, among others that were markedly modulated during the course of the SARS-CoV-2 infection in vitro. Western blot validation of the downstream effector molecules of these pathways revealed a significant reduction in activated S6K1 and 4E-BP1 at 72 hours post infection. Unlike other human respiratory viruses, we found a significant inhibition of HIF-1 through the entire time course of the infection, suggesting a crosstalk between the SARS-CoV-2 and the mTOR/HIF-1 signaling. Further investigations are required to better understand the molecular sequelae in order to guide potential therapy in the management of severe COVID-19 patients.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint